Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Biochem Cell Biol ; 102(3): 226-237, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38377487

ABSTRACT

We here describe the structure-based design of small molecule inhibitors of the type IV secretion system of Helicobacter pylori. The secretion system is encoded by the cag pathogenicity island, and we chose Cagα, a hexameric ATPase and member of the family of VirB11-like proteins, as target for inhibitor design. We first solved the crystal structure of Cagα in a complex with the previously identified small molecule inhibitor 1G2. The molecule binds at the interface between two Cagα subunits and mutagenesis of the binding site identified Cagα residues F39 and R73 as critical for 1G2 binding. Based on the inhibitor binding site we synthesized 98 small molecule derivates of 1G2 to improve binding of the inhibitor. We used the production of interleukin-8 of gastric cancer cells during H. pylori infection to screen the potency of inhibitors and we identified five molecules (1G2_1313, 1G2_1338, 1G2_2886, 1G2_2889, and 1G2_2902) that have similar or higher potency than 1G2. Differential scanning fluorimetry suggested that these five molecules bind Cagα, and enzyme assays demonstrated that some are more potent ATPase inhibitors than 1G2. Finally, scanning electron microscopy revealed that 1G2 and its derivatives inhibit the assembly of T4SS-determined extracellular pili suggesting a mechanism for their anti-virulence effect.


Subject(s)
Adenosine Triphosphatases , Bacterial Proteins , Helicobacter pylori , Helicobacter pylori/enzymology , Humans , Adenosine Triphosphatases/antagonists & inhibitors , Adenosine Triphosphatases/metabolism , Adenosine Triphosphatases/chemistry , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/metabolism , Bacterial Proteins/chemistry , Small Molecule Libraries/pharmacology , Small Molecule Libraries/chemistry , Type IV Secretion Systems/metabolism , Type IV Secretion Systems/chemistry , Type IV Secretion Systems/antagonists & inhibitors , Drug Design , Helicobacter Infections/drug therapy , Helicobacter Infections/microbiology , Crystallography, X-Ray , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/chemistry , Models, Molecular , Binding Sites , Structure-Activity Relationship , Cell Line, Tumor , Interleukin-8/metabolism
2.
Proc Natl Acad Sci U S A ; 119(1)2022 01 04.
Article in English | MEDLINE | ID: mdl-34983846

ABSTRACT

Many soil-, water-, and plant-associated bacterial species from the orders Xanthomonadales, Burkholderales, and Neisseriales carry a type IV secretion system (T4SS) specialized in translocating effector proteins into other gram-negative species, leading to target cell death. These effectors, known as X-Tfes, carry a carboxyl-terminal domain of ∼120 residues, termed XVIPCD, characterized by several conserved motifs and a glutamine-rich tail. Previous studies showed that the XVIPCD is required for interaction with the T4SS coupling protein VirD4 and for T4SS-dependent translocation. However, the structural basis of the XVIPCD-VirD4 interaction is unknown. Here, we show that the XVIPCD interacts with the central all-alpha domain of VirD4 (VirD4AAD). We used solution NMR spectroscopy to solve the structure of the XVIPCD of X-TfeXAC2609 from Xanthomonas citri and to map its interaction surface with VirD4AAD Isothermal titration calorimetry and in vivo Xanthomonas citri versus Escherichia coli competition assays using wild-type and mutant X-TfeXAC2609 and X-TfeXAC3634 indicate that XVIPCDs can be divided into two regions with distinct functions: the well-folded N-terminal region contains specific conserved motifs that are responsible for interactions with VirD4AAD, while both N- and carboxyl-terminal regions are required for effective X-Tfe translocation into the target cell. The conformational stability of the N-terminal region is reduced at and below pH 7.0, a property that may facilitate X-Tfe unfolding and translocation through the more acidic environment of the periplasm.


Subject(s)
Anti-Bacterial Agents/chemistry , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/chemistry , Escherichia coli/chemistry , Type IV Secretion Systems/antagonists & inhibitors , Type IV Secretion Systems/chemistry , Xanthomonas/chemistry , Bacterial Proteins/genetics , Escherichia coli/genetics , Models, Molecular , Mutation , Nuclear Magnetic Resonance, Biomolecular , Protein Domains , Structure-Activity Relationship , Type IV Secretion Systems/genetics , Xanthomonas/genetics
3.
Chembiochem ; 22(18): 2783-2790, 2021 09 14.
Article in English | MEDLINE | ID: mdl-34169626

ABSTRACT

Chronic infection with Helicobacter pylori increases risk of gastric diseases including gastric cancer. Despite development of a robust immune response, H. pylori persists in the gastric niche. Progression of gastric inflammation to serious disease outcomes is associated with infection with H. pylori strains which encode the cag Type IV Secretion System (cag T4SS). The cag T4SS is responsible for translocating the oncogenic protein CagA into host cells and inducing pro-inflammatory and carcinogenic signaling cascades. Our previous work demonstrated that nutrient iron modulates the activity of the T4SS and biogenesis of T4SS pili. In response to H. pylori infection, the host produces a variety of antimicrobial molecules, including the iron-binding glycoprotein, lactoferrin. Our work shows that apo-lactoferrin exerts antimicrobial activity against H. pylori under iron-limited conditions, while holo-lactoferrin enhances bacterial growth. Culturing H. pylori in the presence of holo-lactoferrin prior to co-culture with gastric epithelial cells, results in repression of the cag T4SS activity. Concomitantly, a decrease in biogenesis of cag T4SS pili at the host-pathogen interface was observed under these culture conditions by high-resolution electron microscopy analyses. Taken together, these results indicate that acquisition of alternate sources of nutrient iron plays a role in regulating the pro-inflammatory activity of a bacterial secretion system and present novel therapeutic targets for the treatment of H. pylori-related disease.


Subject(s)
Helicobacter pylori/drug effects , Lactoferrin/pharmacology , Type IV Secretion Systems/metabolism , Animals , Disease Models, Animal , Epithelial Cells/cytology , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Gastric Mucosa/cytology , Gastric Mucosa/metabolism , Gerbillinae , Helicobacter Infections/drug therapy , Helicobacter Infections/microbiology , Helicobacter pylori/metabolism , Immunity, Innate , Interleukin-8/metabolism , Iron/metabolism , Lactoferrin/chemistry , Lactoferrin/metabolism , Lactoferrin/therapeutic use , Protein Isoforms/chemistry , Protein Isoforms/metabolism , Protein Isoforms/pharmacology , Protein Isoforms/therapeutic use , Type IV Secretion Systems/antagonists & inhibitors
4.
Proc Natl Acad Sci U S A ; 118(18)2021 05 04.
Article in English | MEDLINE | ID: mdl-33903242

ABSTRACT

Infection with obligatory intracellular bacteria is difficult to treat, as intracellular targets and delivery methods of therapeutics are not well known. Ehrlichia translocated factor-1 (Etf-1), a type IV secretion system (T4SS) effector, is a primary virulence factor for an obligatory intracellular bacterium, Ehrlichia chaffeensis In this study, we developed Etf-1-specific nanobodies (Nbs) by immunizing a llama to determine if intracellular Nbs block Etf-1 functions and Ehrlichia infection. Of 24 distinct anti-Etf-1 Nbs, NbD7 blocked mitochondrial localization of Etf-1-GFP in cotransfected cells. NbD7 and control Nb (NbD3) bound to different regions of Etf-1. Size-exclusion chromatography showed that the NbD7 and Etf-1 complex was more stable than the NbD3 and Etf-1 complex. Intracellular expression of NbD7 inhibited three activities of Etf-1 and E. chaffeensis: up-regulation of mitochondrial manganese superoxide dismutase, reduction of intracellular reactive oxygen species, and inhibition of cellular apoptosis. Consequently, intracellular NbD7 inhibited Ehrlichia infection, whereas NbD3 did not. To safely and effectively deliver Nbs into the host cell cytoplasm, NbD7 was conjugated to cyclized cell-permeable peptide 12 (CPP12-NbD7). CPP12-NbD7 effectively entered mammalian cells and abrogated the blockade of cellular apoptosis caused by E. chaffeensis and inhibited infection by E. chaffeensis in cell culture and in a severe combined-immunodeficiency mouse model. Our results demonstrate the development of an Nb that interferes with T4SS effector functions and intracellular pathogen infection, along with an intracellular delivery method for this Nb. This strategy should overcome current barriers to advance mechanistic research and develop therapies complementary or alternative to the current broad-spectrum antibiotic.


Subject(s)
Ehrlichia chaffeensis/drug effects , Ehrlichiosis/drug therapy , Single-Domain Antibodies/pharmacology , Type IV Secretion Systems/genetics , Animals , Apoptosis/genetics , B-Lymphocyte Subsets/immunology , Ehrlichia chaffeensis/genetics , Ehrlichia chaffeensis/immunology , Ehrlichia chaffeensis/pathogenicity , Ehrlichiosis/genetics , Ehrlichiosis/immunology , Ehrlichiosis/pathology , Host-Pathogen Interactions/genetics , Host-Pathogen Interactions/immunology , Humans , Mice , Reactive Oxygen Species/metabolism , Single-Domain Antibodies/immunology , Type IV Secretion Systems/antagonists & inhibitors , Type IV Secretion Systems/immunology , Virulence Factors
5.
mBio ; 11(3)2020 06 30.
Article in English | MEDLINE | ID: mdl-32605987

ABSTRACT

The Helicobacter pylori Cag type IV secretion system (T4SS) translocates the effector protein CagA and nonprotein bacterial constituents into host cells. In this study, we infected Mongolian gerbils with an H. pylori strain in which expression of the cagUT operon (required for Cag T4SS activity) is controlled by a TetR/tetO system. Transcript levels of cagU were significantly higher in gastric tissue from H. pylori-infected animals receiving doxycycline-containing chow (to derepress Cag T4SS activity) than in tissue from infected control animals receiving drug-free chow. At 3 months postinfection, infected animals receiving doxycycline had significantly increased gastric inflammation compared to infected control animals. Dysplasia (a premalignant histologic lesion) and/or invasive gastric adenocarcinoma were detected only in infected gerbils receiving doxycycline, not in infected control animals. We then conducted experiments in which Cag T4SS activity was derepressed during defined stages of infection. Continuous Cag T4SS activity throughout a 3-month time period resulted in higher rates of dysplasia and/or gastric cancer than observed when Cag T4SS activity was limited to early or late stages of infection. Cag T4SS activity for the initial 6 weeks of infection was sufficient for the development of gastric inflammation at the 3-month time point, with gastric cancer detected in a small proportion of animals. These experimental results, together with previous studies of cag mutant strains, provide strong evidence that Cag T4SS activity contributes to gastric carcinogenesis and help to define the stages of H. pylori infection during which Cag T4SS activity causes gastric alterations relevant for cancer pathogenesis.IMPORTANCE The "hit-and-run model" of carcinogenesis proposes that an infectious agent triggers carcinogenesis during initial stages of infection and that the ongoing presence of the infectious agent is not required for development of cancer. H. pylori infection and actions of CagA (an effector protein designated a bacterial oncoprotein, secreted by the Cag T4SS) are proposed to constitute a paradigm for hit-and-run carcinogenesis. In this study, we report the development of methods for controlling H. pylori Cag T4SS activity in vivo and demonstrate that Cag T4SS activity contributes to gastric carcinogenesis. We also show that Cag T4SS activity during an early stage of infection is sufficient to initiate a cascade of cellular alterations leading to gastric inflammation and gastric cancer at later time points.


Subject(s)
Antigens, Bacterial/genetics , Bacterial Proteins/genetics , Carcinogenesis , Helicobacter pylori/drug effects , Stomach Neoplasms/microbiology , Type IV Secretion Systems/genetics , Animals , Antigens, Bacterial/metabolism , Bacterial Proteins/metabolism , Disease Models, Animal , Doxycycline/therapeutic use , Gerbillinae/microbiology , Helicobacter Infections/drug therapy , Helicobacter pylori/pathogenicity , Male , Operon/genetics , Type IV Secretion Systems/antagonists & inhibitors
6.
Sci Rep ; 7(1): 14907, 2017 11 02.
Article in English | MEDLINE | ID: mdl-29097752

ABSTRACT

The increasing frequency of antimicrobial resistance is a problem of global importance. Novel strategies are urgently needed to understand and inhibit antimicrobial resistance gene transmission that is mechanistically related to bacterial virulence functions. The conjugative transfer of plasmids by type IV secretion systems is a major contributor to antimicrobial resistance gene transfer. Here, we present a structure-based strategy to identify inhibitors of type IV secretion system-mediated bacterial conjugation. Using differential scanning fluorimetry we screened a fragment library and identified molecules that bind the essential TraE protein of the plasmid pKM101 conjugation machinery. Co-crystallization revealed that fragments bind two alternative sites of the protein and one of them is a novel inhibitor binding site. Based on the structural information on fragment binding we designed novel small molecules that have improved binding affinity. These molecules inhibit the dimerization of TraE, bind to both inhibitor binding sites on TraE and inhibit the conjugative transfer of plasmid pKM101. The strategy presented here is generally applicable for the structure-based design of inhibitors of antimicrobial resistance gene transfer and of bacterial virulence.


Subject(s)
Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Bacterial Proteins/antagonists & inhibitors , Conjugation, Genetic/drug effects , Plasmids/genetics , Type IV Secretion Systems/antagonists & inhibitors , Bacteria/genetics , Bacteria/metabolism , Bacterial Infections/drug therapy , Bacterial Infections/microbiology , Bacterial Proteins/metabolism , Drug Design , Drug Discovery/methods , Drug Resistance, Bacterial/drug effects , Humans , Models, Molecular , Molecular Docking Simulation , Molecular Targeted Therapy , Protein Multimerization/drug effects , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacology , Type IV Secretion Systems/metabolism
7.
J Biol Chem ; 291(45): 23817-23829, 2016 Nov 04.
Article in English | MEDLINE | ID: mdl-27634044

ABSTRACT

Gram-negative bacteria use type IV secretion systems (T4SSs) for a variety of macromolecular transport processes that include the exchange of genetic material. The pKM101 plasmid encodes a T4SS similar to the well-studied model systems from Agrobacterium tumefaciens and Brucella suis Here, we studied the structure and function of TraE, a homolog of VirB8 that is an essential component of all T4SSs. Analysis by X-ray crystallography revealed a structure that is similar to other VirB8 homologs but displayed an altered dimerization interface. The dimerization interface observed in the X-ray structure was corroborated using the bacterial two-hybrid assay, biochemical characterization of the purified protein, and in vivo complementation, demonstrating that there are different modes of dimerization among VirB8 homologs. Analysis of interactions using the bacterial two-hybrid and cross-linking assays showed that TraE and its homologs from Agrobacterium, Brucella, and Helicobacter pylori form heterodimers. They also interact with heterologous VirB10 proteins, indicating a significant degree of plasticity in the protein-protein interactions of VirB8-like proteins. To further assess common features of VirB8-like proteins, we tested a series of small molecules derived from inhibitors of Brucella VirB8 dimerization. These molecules bound to TraE in vitro, docking predicted that they bind to a structurally conserved surface groove of the protein, and some of them inhibited pKM101 plasmid transfer. VirB8-like proteins thus share functionally important sites, and these can be exploited for the design of specific inhibitors of T4SS function.


Subject(s)
Bacterial Proteins/chemistry , Gram-Negative Bacteria/chemistry , Plasmids/chemistry , Type IV Secretion Systems/chemistry , Agrobacterium tumefaciens/chemistry , Agrobacterium tumefaciens/metabolism , Amino Acid Sequence , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/metabolism , Brucella suis/chemistry , Brucella suis/metabolism , Crystallography, X-Ray , Gram-Negative Bacteria/metabolism , Helicobacter pylori/chemistry , Helicobacter pylori/metabolism , Models, Molecular , Plasmids/antagonists & inhibitors , Plasmids/metabolism , Protein Conformation , Protein Interaction Maps , Protein Multimerization , Small Molecule Libraries/pharmacology , Type IV Secretion Systems/antagonists & inhibitors , Type IV Secretion Systems/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...